View Financial HealthNexgenRx 配当と自社株買い配当金 基準チェック /36NexgenRx配当を支払う会社であり、現在の利回りは4.41%です。主要情報4.4%配当利回り0%バイバック利回り総株主利回り4.4%将来の配当利回りn/a配当成長20.7%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向101%最近の配当と自社株買いの更新お知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.すべての更新を表示Recent updatesお知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.お知らせ • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.お知らせ • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.お知らせ • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.お知らせ • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.お知らせ • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.お知らせ • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.お知らせ • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.決済の安定と成長配当データの取得安定した配当: NEGX.Fは 10 年未満配当金を支払っており、この間、支払額は 変動性 が高かった。増加する配当: NEGX.Fは4年間のみ配当金を支払っており、それ以降は支払額が減少しています。配当利回り対市場NexgenRx 配当利回り対市場NEGX.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NEGX.F)4.4%市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Insurance)2.6%アナリスト予想 (NEGX.F) (最長3年)n/a注目すべき配当: NEGX.Fの配当金 ( 4.41% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) よりも高くなっています。高配当: NEGX.Fの配当金 ( 4.41% ) はUS市場 ( 4.25% ) の配当支払者の中で上位 25% に入っています。株主への利益配当収益カバレッジ: NEGX.Fは高い 配当性向 ( 100.8% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: NEGX.Fは低い 現金配当性向 ( 23% ) であるため、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 11:03終値2026/03/23 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NexgenRx Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.
お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.
お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.
お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.
お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.
お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.
お知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.
お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.
お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.
お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.
お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.
お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.
お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.
お知らせ • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.
お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.
お知らせ • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.
お知らせ • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.
お知らせ • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.
お知らせ • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.
お知らせ • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.
お知らせ • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.